Company Insights

CRDL supplier relationships

Explore interactive graphBrowse insights index
CRDL supplier relationship map

Cardiol Therapeutics (CRDL): The supplier ledger investors need to track

Cardiol Therapeutics operates as a clinical-stage biopharma developing anti-inflammatory and anti-fibrotic therapies for cardiovascular disease and monetizes primarily through equity financings and licensing/partnership outcomes tied to clinical progress. The company’s supplier relationships are dominated by capital markets intermediaries that underwrite equity raises and a small set of clinical-service vendors that execute trials — together these suppliers determine CRDL’s access to capital and its ability to advance late-stage clinical programs. For a concise supplier-risk check and relationship map, visit NullExposure homepage.

Market takeaway: CRDL’s supplier profile reads like a financing-first biotech — underwriter concentration and repeated bought-deal structures matter for dilution risk, timing and cost of capital; clinical CRO links matter for program execution.

Why supplier relationships drive value in a capital-intensive biotech

CRDL has near-zero revenue and negative EBITDA, so capital markets partners are functionally critical suppliers: they control fundraising cadence, pricing, and market access. Historical press releases show repeated bought-deal financings led by a single firm in 2026 and syndicate-led offerings in prior years; that pattern signals a fundraising playbook that prioritizes speed and guaranteed proceeds at the expense of potential pricing upside.

Operationally, CRDL’s supplier posture reflects:

  • Contracting style: preference for bought-deal and sole-underwriter agreements that guarantee proceeds and speed execution.
  • Concentration: heavy repeat use of one major underwriter in 2026, with past syndicate arrangements indicating occasional diversification.
  • Criticality: underwriters are mission-critical for near-term survival; clinical CROs are mission-critical for program timelines.
  • Maturity: relationship history spans at least 2018–2026, showing an established — if financing-dependent — supplier ecosystem.

If you’re evaluating counterparty risk or negotiating terms with CRDL, these are the levers that determine dilution, execution risk and strategic optionality. For a full corporate-supplier audit, see NullExposure homepage.

Detailed supplier relationship log (every item in the record)

Below are every supplier relationship entry captured in publicly reported releases. Each item is a plain-English summary with a source citation.

Canaccord Genuity — Newsfile release on closing of US$13.5M public offering (FY2024). Canaccord Genuity acted as sole bookrunner for the offering announced in the release. Source: Newsfile press release (March 2026).

Canaccord Genuity Corp. — Bought-deal financing for gross proceeds of US$13.5M (FY2026). Canaccord agreed to purchase 10,384,616 units at $1.30 per unit on a bought-deal basis as sole underwriter and sole bookrunner. Source: Newsfile press release announcing the bought-deal (March 2026).

Canaccord Genuity Corp. — Closing of bought-deal financing and exercise of over-allotment for gross proceeds of US$14.85M (FY2026). The firm acted as sole underwriter and sole bookrunner for the closed transaction, including full exercise of the over-allotment option. Source: Newsfile press release (March 2026).

Canaccord Genuity — Preliminary prospectus supplement filing for proposed public offering (FY2024). Canaccord is listed as acting as sole bookrunner in connection with the proposed public offering described in the prospectus supplement filing. Source: InvestingNews coverage (March 2026).

Canaccord Genuity — Coverage noting sole bookrunner status for a closed offering (FY2024). Reporting reiterated that Canaccord served as sole bookrunner for the offering. Source: ProactiveInvestors article (March 2026).

Cantor Fitzgerald — Joint bookrunner in a historic offering (FY2021). Cantor Fitzgerald served alongside Canaccord as joint bookrunner in a prior $50M public offering, indicating past use of multi-bank syndicates. Source: IRW-Press report on the FY2021 offering (archival release).

Raymond James Ltd. — Lead underwriter for a $22M bought-deal offering (FY2021). Raymond James led a syndicate as lead underwriter and sole bookrunner for a bought-deal that included regional partners. Source: Newsfile press release on the $22M bought-deal (FY2021).

StockTitan summary — Canaccord Genuity Corp. acted as sole underwriter and sole bookrunner for a bought-deal financing (FY2026). External aggregator echoed that Canaccord led the FY2026 bought-deal financing. Source: StockTitan news summary (March 2026).

Canaccord Genuity — InvestingNews coverage of sole bookrunner role (FY2024). InvestingNews similarly reported Canaccord’s sole bookrunner role for the FY2024 offering. Source: InvestingNews article (March 2026).

Canaccord Genuity Corp. — Disclosure of a 6% commission on the offering (FY2026). Reporting of the bought-deal noted that the company agreed to pay the underwriter a cash commission equal to 6% of gross proceeds upon closing. Source: InvestingNews coverage of the bought-deal terms (March 2026).

Worldwide Clinical Trials — CRO appointment for a Phase II/III outcomes trial (FY2018). Cardiol engaged Worldwide Clinical Trials as the CRO for a high-risk outcomes trial, signaling early-stage operational supplier relationships for clinical execution. Source: SimplyWall.st summary of the 2018 CRO appointment (archived press).

ATB Capital Markets Inc. — Member of the syndicate in the $22M bought-deal (FY2021). ATB Capital Markets participated alongside Raymond James and Leede Jones Gable in the syndicate that completed the bought-deal. Source: Newsfile press release on the FY2021 bought-deal.

Leede Jones Gable Inc. — Syndicate participant in FY2021 bought-deal. Leede Jones Gable was named as part of the underwriting syndicate for the $22M transaction led by Raymond James. Source: Newsfile press release (FY2021).

Canaccord Genuity — IRW-Press coverage of joint bookrunner role in the $50M offering (FY2021). Reporting identified Canaccord and Cantor Fitzgerald as joint bookrunners for the larger public offering completed in 2021. Source: IRW-Press article summarizing the FY2021 deal.

Canaccord Genuity — InvestingNews reporting of exercise and closing of an over-allotment option (FY2024). InvestingNews noted Canaccord acted as sole bookrunner in connection with the over-allotment exercise and closing. Source: InvestingNews article (FY2024).

What the relationship map tells investors and operators

  • Capital markets supply is concentrated and repeatable. Canaccord’s repeated role in 2024–2026, including as sole underwriter on bought-deal financings, signals a primary banking relationship used to secure quick, guaranteed liquidity. That concentration reduces placement risk but increases dependence on one counterparty for execution and pricing.
  • Bought-deal posture reduces timing risk but increases dilution certainty. The FY2026 bought-deal structure and the reported 6% commission are explicit cost-of-capital signals; CRDL trades execution certainty for an explicit fee and fixed pricing.
  • Syndicate history shows flexibility when needed. Earlier syndicate-led deals with Raymond James, Leede Jones Gable and ATB indicate the company can expand its underwriting roster when a larger or diversified placement is desirable.
  • Operational suppliers are limited but important. The appointment of Worldwide Clinical Trials in 2018 demonstrates a history of outsourcing critical trial operations, which impacts program timelines and regulatory readiness.

Mid-article action: if you’re mapping counterparty risk for CRDL or preparing diligence for a financing or partnership, review the full supplier log and scoring tools on NullExposure homepage.

Final investment implications and next steps

CRDL is a financing-driven clinical-stage company where underwriter relationships and CRO partners directly determine runway and program execution. Investors should watch the next underwriting engagements, commission and over-allotment mechanics, and any shifts away from a single lead underwriter as signals of strategic flexibility or distress.

For immediate due diligence, use NullExposure’s supplier risk tools to benchmark counterparty concentration and historical deal terms: https://nullexposure.com/.

Key recommendation: track underwriting announcements and CRO contracts as early indicators of dilution events or trial timeline shifts — those are the levers that will move CRDL’s valuation and clinical milestones. For a structured supplier-risk review and ongoing monitoring, visit NullExposure homepage.